GY48LS6

Кеймбридж
[ ]
Вакцина SARS-CoV-2 inactivated vaccine
Международное непатентованное наименование Вакцина SARS-CoV-2 inactivated vaccine
Торговое наименование -
Производитель, страна Sinovac Research and Development Co., China
Механизм действия

Inactive viral vaccines are created by propagating viruses in cell culture (such as in Vero cells) followed by inactivation using a chemical reagent (such as beta-propiolactone). Upon vaccination, this allows the body to generate a diverse immune response against numerous viral antigens while having no threat of actually being infected because the virus is inactive.

Публикации COVID-19

Qiang GaoLinlin Bao, et al. Rapid Development of an Inactivated Vaccine Candidate for SARS-CoV-2. Science. 2020 May 6;eabc1932. DOI: 10.1126/science.abc1932. 

 

Emma Risson. Inactivated Vaccine for SARS-CoV-2. Nat Rev Immunol. 2020 Apr 30;1. DOI: 10.1038/s41577-020-0334-1. 

Клинические исследования
1.
Название протокола A Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅰ/Ⅱ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 Years
Дата начала и окончания КИ April 16, 2020 - December 13, 2020
Название организации, проводящей КИ Sinovac Research & Development Co.
Страны China
Фаза I-II
Кол-во пациентов 744